Drug Development Solutions Biomarkers (LC-MS & ligand binding) Biomarkers are increasingly important in the development of pharmaceuticals and have a wide range of potential clinical utilities. In particular, an effective biomarker/s can assist in early phase decision making, as serve as an indicator/s of patient safety and drug efficacy. We have a wealth of experience in detection and quantitation of biomarkers in a wide variety of matrices. Tailored services to match your clinical package We have a proven track record of supporting studies in a wide range of therapeutic areas such as metabolic disorders (including diabetes and cardiovascular disease), inflammatory disorders (including rheumatoid arthritis), respiratory diseases (including chronic obstructive pulmonary disease) and anti- infectives. We can tailor your qualifications and validations to match the needs of your clinical program. Biomarkers are re-shaping drug development Our biomarker services can be adapted to your specific requirements: • Assay development - Feasibility assessment, establishment and development with a wide variety of analytical methodologies, species and matrices. • Validation - Leading expertise in helping clients develop the most appropriate strategies for validation based on the purpose of the biomarker. We validate both in-house and commercial assays to GCP or GLP standards in line with current regulations. • Quantification - As a measure of drug safety or efficacy, or to prove a new drug’s mechanism of action. We have the capability for small and large molecules, molecular diagnostics and cell based assays. • Capacity - As a pioneer in new analytical approaches and technology, we have invested in a broad range of analytical platforms and have one of the largest bioanalytical facilities with more than 200 scientists dedicated to drug development. This allows us to deliver a broad range biomarker solutions including the most large and complex clinical programmes.